#United States #San Francisco #Hagens Berman #aTyr Pharma #Efzofitimod

Legal Alert: ATYR Pharma Investors Must Act Soon

Investors holding shares of aTyr Pharma, Inc. (NASDAQ: ATYR) should take heed as the law firm Hagens Berman has issued an urgent reminder regarding the deadline for filing claims related to a significant securities class action lawsuit. The deadline for investors to move the Court for lead plaintiff appointment is December 8, 2025. This case stems from a major trial failure of the company's flagship drug, Efzofitimod, which led to a staggering 83% drop in its stock value within a single trading day.

The Context of the Case

On September 15, 2025, aTyr Pharma disclosed the unfortunate results from the Phase 3 EFZO-FIT clinical trial, which failed to reach its primary endpoint. This revelation sent shockwaves through the market as the stock plummeted from $6.03 to $1.02, causing heavy financial losses for investors. Allegations detailed in the lawsuit claim that aTyr and its executives misled investors regarding the efficacy of Efzofitimod, prompting them to purchase shares at inflated prices based on materially false representations. Reed Kathrein, a partner at Hagens Berman leading this litigation, emphasized the importance of a thorough examination of whether the claims made by aTyr were indeed misleading, and thus, violative of securities laws.

Key Allegations

In the ongoing litigation, several critical points have emerged:

• - Primary Endpoint Failure: The trial did not meet its primary endpoint, which measured the change from baseline in mean daily oral corticosteroid (OCS) dosage. This raises questions about how aTyr represented the drug’s capabilities to effectively reduce steroid dependency in patients.

• - Concealed Efficacy: The company allegedly withheld adverse information about the drug's effectiveness, specifically its ability to enable patients to entirely taper off steroids—a core measure of success in the eyes of both scientists and investors alike.

• - Market Impact Analysis: The drastic price drop of over 83% on the day the news broke underlines the material impact of the company’s alleged misstatements. The lawsuit's focus includes whether investors can seek damages for these losses, attributed to the company’s purported wrongful actions and omissions.

What Investors Should Do

For investors who purchased ATYR shares during the Class Period, which spans from November 7, 2024, to September 12, 2025, and experienced significant financial losses, it is imperative to act swiftly. Hagens Berman recommends that these investors contact them as soon as possible to discuss their eligibility to join the class action. The firm has a strong track record of securing more than $2.9 billion in settlements on behalf of investors, highlighting their expertise in navigating complex securities litigation.

Next Steps: Engage with Hagens Berman

Hagens Berman is committed to supporting investors affected by the alleged misrepresentation of aTyr’s drug efficacy. They encourage those impacted to submit their claims through a secure form provided by the firm before the impending December 8 deadline. Additionally, whistleblowers or individuals with non-public information regarding aTyr are encouraged to step forward, as they may be considered for rewards under the SEC Whistleblower program that can reach up to 30% of successful recoveries from their disclosures.

In summary, as deadlines approach and legal actions unfold, it’s crucial for aTyr Pharma investors to keep informed and take necessary actions to protect their rights in light of recent developments concerning the company’s troubled trials and subsequent legal implications.